{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:12:36Z","timestamp":1789668756829,"version":"4.0.1"},"reference-count":249,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118440","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:23:14Z","timestamp":1788733394000},"page":"118440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Acute leukemia therapy at a crossroads: from conventional chemotherapy to the era of precision medicine"],"prefix":"10.1016","volume":"254","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-3250","authenticated-orcid":false,"given":"Naoko","family":"Hosono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Ida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118440_b0005","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cpt196455574","article-title":"Clinical trial of hydroxyurea in patients with cancer and leukemia","volume":"5","author":"Fishbein","year":"1964","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2026.118440_b0010","first-page":"535","article-title":"Inhibition of DNA synthesis by hydroxyurea: structure-activity relationships","volume":"27","author":"Young","year":"1967","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118440_b0015","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/201706a0","article-title":".\u2018Daunomycin\u2019, a new antibiotic of the rhodomycin grou","volume":"201","author":"Di Marco","year":"1964","journal-title":"Nature"},{"issue":"7590","key":"10.1016\/j.bcp.2026.118440_b0020","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0140-6736(69)91296-3","article-title":"Daunorubicin in the treatment of acute myelocytic leukemia","volume":"293","author":"Boiron","year":"1969","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118440_b0025","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V32.4.507.507","article-title":"Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults","author":"Ellison","year":"1968","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bcp.2026.118440_b0030","first-page":"485","article-title":"Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates","year":"1973","journal-title":"Cancer Chemother. Rep."},{"issue":"5","key":"10.1016\/j.bcp.2026.118440_b0035","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","article-title":"Therapeutic advances in acute myeloid leukemia","volume":"29","author":"Burnett","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"7218","key":"10.1016\/j.bcp.2026.118440_b0040","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/nature07485","article-title":"DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome","volume":"456","author":"Ley","year":"2008","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.bcp.2026.118440_b0045","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"The Cancer Genome Atlas Research Network","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.bcp.2026.118440_b0050","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"7382","key":"10.1016\/j.bcp.2026.118440_b0055","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"issue":"7488","key":"10.1016\/j.bcp.2026.118440_b0060","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukemic hematopoietic stem cells in acute leukemia","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bcp.2026.118440_b0065","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bcp.2026.118440_b0070","first-page":"1800","article-title":"A new sensitive method for determination of intracellular 1-\u03b2-D-arabinofuranosylcytosine 5'-triphosphate content in human materials in vivo","volume":"56","author":"Yamauchi","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118440_b0075","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.bcp.2009.03.011","article-title":"Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase \/ cytosolic 5\u2019-nucleotidase II expression ratio in primary acute myeloid leukemia cells","volume":"77","author":"Yamauchi","year":"2009","journal-title":"Biochem. Pharmacol."},{"issue":"1795\u20131803","key":"10.1016\/j.bcp.2026.118440_b0080","first-page":"6","article-title":"A sensitive new method for clinically monitoring cytarabine concentrations at the DNA level in leukemic cells","volume":"69","author":"Yamauchi","year":"2005","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118440_b0085","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1200\/JCO.1986.4.8.1207","article-title":"Systemic high-dose ara-C for the treatment of meningeal leukemia in adult acute lymphoblastic leukemia and non-Hodgkin's lymphoma","volume":"4","author":"Morra","year":"1986","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118440_b0090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0268-960X(97)90005-9","article-title":"High-dose cytosine arabinoside in the treatment of acute myeloid leukaemia","volume":"11","author":"Cole","year":"1997","journal-title":"Blood Rev."},{"key":"10.1016\/j.bcp.2026.118440_b0095","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B","volume":"331","author":"Mayer","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118440_b0100","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1186\/s12885-020-07469-x","article-title":"Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine","volume":"20","author":"Nishi","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2026.118440_b0105","first-page":"829","article-title":"Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their beta anomers","volume":"60","author":"Arcamone","year":"1976","journal-title":"Cancer Treat. Rep."},{"issue":"4673","key":"10.1016\/j.bcp.2026.118440_b0110","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1126\/science.6093249","article-title":"Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II","volume":"226","author":"Tewey","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.bcp.2026.118440_b0115","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1021\/bi00260a005","article-title":"Studies on interaction of anthracycline antibiotics and deoxyribonucleic acid: equilibrium binding studies on interaction of daunomycin with deoxyribonucleic acid","volume":"21","author":"Chaires","year":"1982","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2026.118440_b0120","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0167-4781(84)90040-X","article-title":"The binding of actinomycin D and Adriamycin to supercoiled DNA, single-stranded DNA and polynucleotides","volume":"14","author":"Simpkins","year":"1984","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.bcp.2026.118440_b0125","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2026.118440_b0130","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","article-title":"A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants","volume":"455","author":"Juliano","year":"1976","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bcp.2026.118440_b0135","first-page":"227","article-title":"The mechanism of ATP-dependent multidrug transport by P-glycoprotein","volume":"643","author":"Shapiro","year":"1998","journal-title":"Acta Physiol. Scand. Suppl."},{"issue":"1","key":"10.1016\/j.bcp.2026.118440_b0140","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0092-8674(91)90141-K","article-title":"Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells","volume":"66","author":"Chaudhary","year":"1991","journal-title":"Cell"},{"issue":"16","key":"10.1016\/j.bcp.2026.118440_b0145","first-page":"4403","article-title":"Human acute myeloid leukemia CD34+\/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities","volume":"60","author":"Costello","year":"2000","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.118440_b0150","first-page":"1086","article-title":"Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1\/P-glycoprotein, MRP1, and LRP in 135 patients with de novo and secondary acute myeloid leukemia: a Southwest Oncology Group study","volume":"94","author":"Leith","year":"1999","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bcp.2026.118440_b0155","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/nm.4210","article-title":"DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling","volume":"22","author":"Guryanova","year":"2016","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118440_b0160","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0092-8674(00)80903-4","article-title":"FACT, a factor that facilitates transcript elongation through nucleosomes","volume":"92","author":"Orphanides","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.118440_b0165","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline Dose Intensification in Acute Myeloid Leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118440_b0170","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bcp.2026.118440_b0175","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1158\/1078-0432.CCR-14-0327","article-title":"DNMT3A mutational status affects the results of dose-escalated induction therapy in acute myelogenous leukemia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.bcp.2026.118440_b0180","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1182\/blood-2012-10-461624","article-title":"Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)","volume":"121","author":"Gaidzik","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2026.118440_b0185","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/leu.2012.168","article-title":"Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report","volume":"27","author":"Ostronoff","year":"2013","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.bcp.2026.118440_b0190","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"L\u00f6wenberg","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118440_b0195","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A Mutations in Acute Myeloid Leukemia","volume":"363","author":"Ley","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bcp.2026.118440_b0200","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/1878-0261.13583","article-title":"Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS-010759","volume":"18","author":"Pujalte-Martin","year":"2024","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118440_b0205","first-page":"129","article-title":"In vivo maintenance of synergistic cytarabine :daunorubicin ratios greatly enhances therapeutic efficacy","volume":"33","author":"Tardi","year":"2009","journal-title":"LeukRes"},{"key":"10.1016\/j.bcp.2026.118440_b0210","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.2147\/IJN.S139450","article-title":"CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties","volume":"14","author":"Mayer","year":"2019","journal-title":"Int. J. Nanomedicine."},{"key":"10.1016\/j.bcp.2026.118440_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2024.104651","article-title":"Cellular uptake of CPX-351 by scavenger receptor class B type 1-mediated nonendocytic pathway","volume":"140","author":"Araie","year":"2024","journal-title":"Exp. Hematol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118440_b0220","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1200\/JCO.2010.30.5961","article-title":"First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia","volume":"29","author":"Feldman","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.bcp.2026.118440_b0225","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118440_b0230","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s12185-024-03733-z","article-title":"A phase 1\/2 study of NS-87\/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia","volume":"119","author":"Usuki","year":"2024","journal-title":"Int. J. Hematol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118440_b0235","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s12185-025-04047-4","article-title":"Safety of liposomal daunorubicin-cytarabine (CPX-351) in secondary AML: Japanese phase 1\/2 study and global phase 3 study","volume":"122","author":"Hosono","year":"2025","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.bcp.2026.118440_b0240","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1080\/1042819021000002866","article-title":"FLT3 in human hematologic malignancies","volume":"43","author":"Kiyoi","year":"2002","journal-title":"Leuk. Lymphoma"},{"issue":"12","key":"10.1016\/j.bcp.2026.118440_b0245","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bcp.2026.118440_b0250","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bcp.2026.118440_b0255","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bcp.2026.118440_b0260","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","article-title":"FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions","volume":"16","author":"Larrosa-Garcia","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"7397","key":"10.1016\/j.bcp.2026.118440_b0265","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nature11016","article-title":"Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia","volume":"485","author":"Smith","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bcp.2026.118440_b0270","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10388","key":"10.1016\/j.bcp.2026.118440_b0275","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"Suppl","key":"10.1016\/j.bcp.2026.118440_b0280","article-title":"Updated results of the VEN-A-QUI study: a phase 1\u20132 trial to assess the safety and efficacy of triplets for newly diagnosed unfit AML patients: azacitidine or low-dose cytarabine with venetoclax and quizartinib","volume":"7","author":"Burgues","year":"2023","journal-title":"Hemasphere."},{"issue":"Supplement 1","key":"10.1016\/j.bcp.2026.118440_b0285","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2022-157210","article-title":"Updated results of a phase 1\/2 study of venetoclax, azacitidine, and gilteritinib in patients with newly diagnosed FLT3-mutated acute myeloid leukemia","volume":"140","author":"Short","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.bcp.2026.118440_b0290","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1182\/blood-2025-654","article-title":"Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1\/2 VICEROY study","volume":"146","author":"Altman","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118440_b0295","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.118440_b0300","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-022-00677-7","article-title":"Clinical outcomes in patients with relapsed\/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib","volume":"12","author":"Perl","year":"2022","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.bcp.2026.118440_b0305","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2016-04-711820","article-title":"Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis","volume":"130","author":"Smith","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bcp.2026.118440_b0310","doi-asserted-by":"crossref","first-page":"E226","DOI":"10.1002\/ajh.26174","article-title":"A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance","volume":"96","author":"Joshi","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118440_b0315","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1182\/bloodadvances.2020001449","article-title":"A phase 1\/2 study of the oral FLT3 inhibitor pexidartinib in relapsed\/refractory FLT3-ITD-mutant acute myeloid leukemia","volume":"4","author":"Smith","year":"2020","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.bcp.2026.118440_b0320","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1158\/1535-7163.MCT-21-0317","article-title":"The irreversible FLT3 inhibitor FF-10101 is active against a diversity of FLT3 inhibitor resistance mechanisms","volume":"21","author":"Ferng","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"10.1016\/j.bcp.2026.118440_b0325","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/nrd2086","article-title":"Targeting the Hedgehog pathway in cancer","volume":"5","author":"Rubin","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2026.118440_b0330","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2011-10-383752","article-title":"Targeting hedgehog in hematologic malignancy","volume":"119","author":"Irvine","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bcp.2026.118440_b0335","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/cas.13019","article-title":"Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells","volume":"107","author":"Fukushima","year":"2016","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.bcp.2026.118440_b0340","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1152\/jn.00822.2014","article-title":"Hedgehog pathway blockade with the cancer drug LDE225 disrupts taste organs and taste sensation","volume":"113","author":"Kumari","year":"2015","journal-title":"J. Neurophysiol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118440_b0345","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.bcp.2026.118440_b0350","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1038\/s41375-023-02001-z","article-title":"Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial","volume":"37","author":"Sekeres","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2026.118440_b0355","first-page":"1758","article-title":"The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics","volume":"5","author":"Kornblau","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118440_b0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108694","article-title":"A Multicenter phase I\/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia","volume":"9","author":"Schimmer","year":"2014","journal-title":"PLoSOne"},{"issue":"10","key":"10.1016\/j.bcp.2026.118440_b0365","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.bcp.2026.118440_b0370","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.bcp.2026.118440_b0375","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118440_b0380","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.118440_b0385","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.bcp.2026.118440_b0390","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1101\/gad.182980.111","article-title":"Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia","volume":"26","author":"Glaser","year":"2012","journal-title":"Genes Dev."},{"issue":"3","key":"10.1016\/j.bcp.2026.118440_b0395","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent BCL2 G101V mutation in establishes resistance to venetoclax in patients with chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.bcp.2026.118440_b0400","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.bcp.2026.118440_b0405","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","article-title":"Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat Cancer."},{"issue":"6","key":"10.1016\/j.bcp.2026.118440_b0410","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","article-title":"Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax","volume":"13","author":"Waclawiczek","year":"2023","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.bcp.2026.118440_b0415","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bcp.2026.118440_b0420","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.stem.2020.07.021","article-title":"Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells","volume":"27","author":"Jones","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bcp.2026.118440_b0425","unstructured":"J. Shortt, C.Y. Fong, S. Leitch, et al., Updated safety and antileukemic activity data of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in treatment-naive patients with acute myeloid leukemia unfit for intensive chemotherapy. PF477. European Hematology Association 2025 Congress."},{"issue":"Supplement 1","key":"10.1016\/j.bcp.2026.118440_b0430","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1182\/blood-2025-1641","article-title":"Results of the APG2575AU101 Study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax\u2013exposed myeloid malignancies","volume":"146","author":"Kadia","year":"2025","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bcp.2026.118440_b0435","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3324\/haematol.2010.025494","article-title":"IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis","volume":"95","author":"Thol","year":"2010","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.bcp.2026.118440_b0440","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"7390","key":"10.1016\/j.bcp.2026.118440_b0445","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.bcp.2026.118440_b0450","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1021\/bi200499m","article-title":"A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of \u03b1HG","volume":"50","author":"Pietrak","year":"2011","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2026.118440_b0455","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1021\/ml300225h","article-title":"Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo","volume":"3","author":"Popovici-Muller","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"issue":"16","key":"10.1016\/j.bcp.2026.118440_b0460","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118440_b0465","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1038\/s41467-022-32436-4","article-title":"Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors","volume":"13","author":"Reinbold","year":"2022","journal-title":"Nat. Commun."},{"issue":"13","key":"10.1016\/j.bcp.2026.118440_b0470","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","article-title":"Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML","volume":"7","author":"Botton","year":"2023","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.bcp.2026.118440_b0475","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/2159-8290.CD-16-1034","article-title":"AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations","volume":"7","author":"Yen","year":"2017","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.bcp.2026.118440_b0480","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118440_b0485","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood.2021014901","article-title":"Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed\/refractory AML: a randomized phase 3 trial","volume":"141","author":"Botton","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bcp.2026.118440_b0490","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/2159-8290.CD-18-0877","article-title":"Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition","volume":"8","author":"Harding","year":"2018","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.bcp.2026.118440_b0495","article-title":"The molecular mechanisms of resistance to IDH inhibitors in acute myeloid leukemia","volume":"23","author":"Zhuang","year":"2022","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118440_b0500","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1182\/bloodadvances.2020001503","article-title":"Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML","volume":"4","author":"Choe","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.bcp.2026.118440_b0505","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118440_b0510","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2018-08-869008","article-title":"Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib","volume":"133","author":"Stein","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118440_b0515","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118440_b0520","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.clml.2016.04.006","article-title":"Evidence for clinical differentiation and differentiation syndrome in patients with acute myeloid leukemia and IDH1 mutations treated with the targeted mutant IDH1 inhibitor, AG-120","volume":"16","author":"Birendra","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"16","key":"10.1016\/j.bcp.2026.118440_b0525","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-20-0834","article-title":"Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a U.S. food and drug administration systematic analysis","volume":"26","author":"Norsworthy","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.bcp.2026.118440_b0530","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.tibs.2013.05.005","article-title":"Menin: a scaffold protein that controls gene expression and cell signaling","volume":"38","author":"Matkar","year":"2013","journal-title":"Trends Biochem. Sci"},{"issue":"5","key":"10.1016\/j.bcp.2026.118440_b0535","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/leu.2012.356","article-title":"The role of HOX genes in normal hematopoiesis and acute leukemia","volume":"27","author":"Alharbi","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bcp.2026.118440_b0540","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/MOH.0000000000000245","article-title":"Deregulation of the HOXA9\/MEIS1 axis in acute leukemia","volume":"23","author":"Collins","year":"2016","journal-title":"Curr. Opin. Hematol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118440_b0545","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The Menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.118440_b0550","doi-asserted-by":"crossref","first-page":"14765","DOI":"10.1073\/pnas.0503630102","article-title":"MLL associates specifically with a subset of transcriptionally active target genes","volume":"102","author":"Milne","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"10","key":"10.1016\/j.bcp.2026.118440_b0555","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1158\/2159-8290.CD-16-0237","article-title":"Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia","volume":"6","author":"Kuhn","year":"2016","journal-title":"Cancer Discov."},{"issue":"7954","key":"10.1016\/j.bcp.2026.118440_b0560","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The Menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118440_b0565","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118440_b0570","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1200\/JCO.2025.43.16_suppl.6506","article-title":"Ziftomenib in relapsed\/refractory (R\/R) NPM1-mutant acute myeloid leukemia (AML): phase 1b\/2 clinical activity and safety results from the pivotal KOMET-001 study","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118440_b0575","unstructured":"National Center for Biotechnology Information. \u201cPubChem Compound Summary for CID 146430058, Dsp-5336 PubChem, https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/146430058. Accessed 4 May, 2026."},{"issue":"Supplement 1","key":"10.1016\/j.bcp.2026.118440_b0580","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood-2025-763","article-title":"Monotherapy update from phase 1 portion in Phase1\/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia","volume":"146","author":"Daver","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bcp.2026.118440_b0585","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2024-207106","article-title":"Bleximenib dose optimization and determination of RP2D from a phase 1 study in relapsed\/refractory acute leukemia patients with KMT2A and NPM1 alterations","volume":"144","author":"Searle","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bcp.2026.118440_b0590","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.3390\/ijms27041775","article-title":"Differentiation syndrome in acute myeloid Leukemia: molecular mechanisms, clinical spectrum, and emerging therapeutic paradigms","volume":"27","author":"Mansour","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118440_b0595","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood.2021012806","article-title":"The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML","volume":"139","author":"Heikamp","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118440_b0600","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2023021359","article-title":"Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors","volume":"143","author":"Barajas","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bcp.2026.118440_b0605","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1038\/s41375-019-0382-3","article-title":"CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex","volume":"33","author":"Schmidt","year":"2019","journal-title":"Leukemia"},{"issue":"7954","key":"10.1016\/j.bcp.2026.118440_b0610","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.bcp.2026.118440_b0615","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood.2023023644","article-title":"Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia","volume":"144","author":"Zhou","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2026.118440_b0620","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2159-8290.CD-22-0416","article-title":"A molecular switch between mammalian MLL complexes dictates response to Menin-MLL inhibition","volume":"13","author":"Soto-Feliciano","year":"2023","journal-title":"Cancer Discov."},{"issue":"21","key":"10.1016\/j.bcp.2026.118440_b0625","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood.2020005037","article-title":"Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition","volume":"136","author":"Dzama","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2026.118440_b0630","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","article-title":"DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia","volume":"17","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.bcp.2026.118440_b0635","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118440_b0640","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bcp.2026.118440_b0645","first-page":"405","article-title":"Biological effects of 5-azacytidine in eukaryotes","volume":"30","author":"Cih\u00e1k","year":"1974","journal-title":"Oncology"},{"issue":"10","key":"10.1016\/j.bcp.2026.118440_b0650","first-page":"959","article-title":"Biochemistry of azacitidine: a review","volume":"71","author":"Glover","year":"1987","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.bcp.2026.118440_b0655","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bcp.2026.118440_b0660","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.seminoncol.2005.07.008","article-title":"Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine)","volume":"32","author":"Momparler","year":"2005","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bcp.2026.118440_b0665","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.bcp.2026.118440_b0670","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1182\/blood-2025-1676","article-title":"10-day decitabine versus conventional chemotherapy (\u201c3+7\u201d) followed by allografting in AML patients \u2265 60 years: long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group","volume":"146","author":"L\u00fcbbert","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118440_b0675","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.2010.34.4226","article-title":"Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118440_b0680","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.bcp.2026.118440_b0685","article-title":"The history of oral decitabine\/cedazuridine and its potential role in acute myeloid leukemia","volume":"17","author":"Briski","year":"2023","journal-title":"Ther. Adv. Hematol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118440_b0690","first-page":"e15","article-title":"Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study","volume":"11","author":"Garcia-Manero","year":"2024","journal-title":"Ancet Haematol."},{"key":"10.1016\/j.bcp.2026.118440_b0695","doi-asserted-by":"crossref","unstructured":"A.M. Zeidan, E.A. Griffiths, C.D. Dinardo, et al., An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts. J Clin Oncol 43, 6504 (2025) Volume 43, Number 16_suppl.","DOI":"10.1200\/JCO.2025.43.16_suppl.6504"},{"issue":"1","key":"10.1016\/j.bcp.2026.118440_b0700","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1021\/bc010021y","article-title":"Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia","volume":"13","author":"Hamann","year":"2002","journal-title":"Bioconjug. Chem."},{"issue":"24","key":"10.1016\/j.bcp.2026.118440_b0705","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"issue":"9825","key":"10.1016\/j.bcp.2026.118440_b0710","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.bcp.2026.118440_b0715","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from 3325 patients in five randomised trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2026.118440_b0720","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.3324\/haematol.2022.281563","article-title":"Results from a phase I\/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy","volume":"108","author":"Pabst","year":"2023","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.bcp.2026.118440_b0725","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41375-025-02642-2","article-title":"KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML","volume":"39","author":"Zou","year":"2025","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.bcp.2026.118440_b0730","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.bcp.2026.118440_b0735","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/1535-7163.MCT-17-0742","article-title":"Characterization of SGN-CD123A, a potent CD123-directed antibody\u2013drug conjugate for acute myeloid leukemia","volume":"17","author":"Li","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"19","key":"10.1016\/j.bcp.2026.118440_b0740","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2018-06-858159","article-title":"Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice","volume":"133","author":"Pang","year":"2019","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.bcp.2026.118440_b0745","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1021\/acs.molpharmaceut.8b00225","article-title":"Metabolism of an oxime-linked antibody drug conjugate, AGS62P1, and characterization of its identified metabolite","volume":"15","author":"Snyder","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bcp.2026.118440_b0750","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2014-05-575704","article-title":"Targeting CD123 in acute myeloid leukemia using a T-cell\u2013directed dual-affinity retargeting platform","volume":"127","author":"Al-Hussaini","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118440_b0755","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118440_b0760","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa5693","article-title":"A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates","volume":"7","author":"Chichili","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"Supplement 1","key":"10.1016\/j.bcp.2026.118440_b0765","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-134746","article-title":"Complete responses in relapsed\/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of vibecotamab (XmAb14045), a CD123 \u00d7 CD3 T cell-engaging bispecific antibody; initial results of a phase 1 study","volume":"136","author":"Ravandi","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bcp.2026.118440_b0770","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/13543784.2018.1452911","article-title":"Investigational CD33-targeted therapeutics for acute myeloid leukemia","volume":"27","author":"Walter","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bcp.2026.118440_b0775","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/10428194.2024.2346755","article-title":"Safety and tolerability of AMG 330 in adults with relapsed\/refractory AML: a phase 1a dose-escalation study","volume":"65","author":"Ravandi","year":"2024","journal-title":"Leuk. Lymphoma"},{"issue":"Supplement_1","key":"10.1016\/j.bcp.2026.118440_b0780","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2019-127977","article-title":"Preliminary results from a phase 1 first-in-human study of AMG 673, a novel half-life extended (HLE) anti-CD33\/CD3 BiTE\u00ae (bispecific t-cell engager) in patients with relapsed\/refractory (R\/R) acute myeloid leukemia (AML)","volume":"134","author":"Subklewe","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.bcp.2026.118440_b0785","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2025-768","article-title":"Preliminary anti-leukemia activity from a phase 1 study of cln-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in Relapsed\/Refractory (R\/R) Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)","volume":"146","author":"Abdul-Hay","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118440_b0790","article-title":"T cell-engaging bispecific antibodies for myeloid malignancies: Targets, formats, and clinical challenges","volume":"27","author":"Paczesny","year":"2026","journal-title":"Cell Rep. Med."},{"issue":"Supplement 1","key":"10.1016\/j.bcp.2026.118440_b0795","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2023-173162","article-title":"First-in-human study of the CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia: updated safety, efficacy, pharmacokinetics and pharmacodynamics","volume":"142","author":"Bajel","year":"2023","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.bcp.2026.118440_b0800","article-title":"Transient mRNA-based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy","volume":"4","author":"Inthanachai","year":"2026","journal-title":"Immunooncol Technol."},{"key":"10.1016\/j.bcp.2026.118440_b0805","unstructured":"Aprea Therapeutics Announces Phase 3 Trial of Eprenetapopt in TP53-Mutant MDS Misses Primary Endpoint. (Press Release, December 2020)."},{"issue":"21","key":"10.1016\/j.bcp.2026.118440_b0810","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1182\/blood.2025028935","article-title":"Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia","volume":"146","author":"Carter","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118440_b0815","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1182\/blood.2022016362","article-title":"Venetoclax and idasanutlin in relapsed\/refractory AML: a nonrandomized, open-label phase 1b trial","volume":"141","author":"Daver","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2026.118440_b0820","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1158\/1078-0432.CCR-22-0978","article-title":"Lisaftoclax in combination with alrizomadlin overcomes venetoclax resistance in acute myeloid leukemia and acute lymphoblastic leukemia: preclinical studies","volume":"29","author":"Zhai","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.118440_b0825","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00277-022-05075-4","article-title":"Molecular response patterns in relapsed\/refractory AML patients treated with selinexor and chemotherapy","volume":"102","author":"Klement","year":"2023","journal-title":"Ann. Hematol."},{"issue":"22","key":"10.1016\/j.bcp.2026.118440_b0830","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.1158\/1078-0432.CCR-20-1064","article-title":"Entospletinib in combination with induction chemotherapy in previously untreated acute myeloid leukemia: response and predictive significance of HOXA9 and MEIS1 expression","volume":"26","author":"Walker","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"Supplement 1","key":"10.1016\/j.bcp.2026.118440_b0835","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2022-159338","article-title":"CTX-712, a novel splicing modulator targeting myeloid neoplasms","volume":"140","author":"Yoda","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bcp.2026.118440_b0840","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/nm.4416","article-title":"The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells","volume":"23","author":"Vu","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.118440_b0845","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.0954-6820.1957.tb00124.x","article-title":"Acute Promyelocytic Leukemia","volume":"159","author":"Hillestad","year":"1957","journal-title":"Acta Med. Scand."},{"key":"10.1016\/j.bcp.2026.118440_b0850","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1002\/cncr.27623","article-title":"Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975\u20132008","volume":"118","author":"Chen","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2026.118440_b0855","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0092-8674(91)90113-D","article-title":"The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR","volume":"66","author":"de The","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.118440_b0860","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood.V72.2.567.567","article-title":"Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia","volume":"72","author":"Huang","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118440_b0865","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood.V88.3.1052.1052","article-title":"In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha\/PML proteins","volume":"88","author":"Chen","year":"1996","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bcp.2026.118440_b0870","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrc2943","article-title":"Acute promyelocytic leukaemia: novel insights into the mechanisms of cure","volume":"10","author":"de Th\u00e9","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"13","key":"10.1016\/j.bcp.2026.118440_b0875","first-page":"2945","article-title":"Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway","volume":"56","author":"Yoshida","year":"1996","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118440_b0880","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s12185-013-1354-4","article-title":"Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia","volume":"97","author":"Tomita","year":"2013","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.bcp.2026.118440_b0885","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2012-01-407601","article-title":"Treatment-influenced associations of PML-RARalpha mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia","volume":"120","author":"Gallagher","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bcp.2026.118440_b0890","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/leu.2016.69","article-title":"Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia","volume":"30","author":"Madan","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bcp.2026.118440_b0895","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1182\/blood.V90.3.967","article-title":"Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid","volume":"90","author":"Tobita","year":"1997","journal-title":"Blood"},{"issue":"5975","key":"10.1016\/j.bcp.2026.118440_b0900","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1126\/science.1183424","article-title":"Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML","volume":"328","author":"Zhang","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.bcp.2026.118440_b0905","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood-2011-01-329433","article-title":"Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment","volume":"118","author":"Goto","year":"2011","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.bcp.2026.118440_b0910","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1056\/NEJMc1316382","article-title":"Resistance to arsenic therapy in acute promyelocytic leukemia","volume":"370","author":"Zhu","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bcp.2026.118440_b0915","first-page":"0696","article-title":"Mutation in the unrearranged PML allele confers resistance to arsenic trioxide in acute promyelocytic leukemia","volume":"6","author":"Yu","year":"2025","journal-title":"Research (WASH D C)."},{"issue":"7","key":"10.1016\/j.bcp.2026.118440_b0920","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1084\/jem.189.7.1043","article-title":"Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia","volume":"189","author":"Lallemand-Breitenbach","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2026.118440_b0925","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"29","key":"10.1016\/j.bcp.2026.118440_b0930","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1200\/JCO-25-01496","article-title":"APOLLO: optimizing the treatment of high-risk acute promyelocytic leukemia with all-trans retinoic acid and arsenic trioxide while minimizing the role of chemotherapy","volume":"43","author":"Iland","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.bcp.2026.118440_b0935","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1200\/JCO.2013.48.8312","article-title":"Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial","volume":"31","author":"Zhu","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118440_b0940","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/bloodadvances.2024014999","article-title":"Acute Promyelocytic Leukemia Asian Consortium study of arsenic trioxide in newly diagnosed patients: impact and outcome","volume":"9","author":"Gill","year":"2025","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.bcp.2026.118440_b0945","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjh.18476","article-title":"Differentiation therapy using low-dose venetoclax in a variant acute promyelocytic leukaemia carrying ZBTB16-RARA","volume":"199","author":"Li","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcp.2026.118440_b0950","doi-asserted-by":"crossref","DOI":"10.1177\/15330338221095950","article-title":"Targeted protein degradation: an important tool for drug discovery for \u201cundruggable\u201d tumor transcription factors","volume":"21","author":"Dai","year":"2022","journal-title":"Technol. Cancer Res. Treat."},{"issue":"7","key":"10.1016\/j.bcp.2026.118440_b0955","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/ajh.27708","article-title":"Adult acute lymphoblastic leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"100","author":"Kantarjian","year":"2025","journal-title":"Am. J. Hematol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118440_b0960","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1038\/s41375-021-01277-3","article-title":"Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms","volume":"35","author":"Short","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bcp.2026.118440_b0965","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","article-title":"A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias","volume":"100","author":"Ottmann","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bcp.2026.118440_b0970","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","article-title":"UKALLXII\/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia","volume":"123","author":"Fielding","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bcp.2026.118440_b0975","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jama.2024.4783","article-title":"Ponatinib vs imatinib in frontline Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"331","author":"Jabbour","year":"2024","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.bcp.2026.118440_b0980","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118440_b0985","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol."},{"issue":"5531","key":"10.1016\/j.bcp.2026.118440_b0990","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bcp.2026.118440_b0995","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood-2006-11-052373","article-title":"Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"110","author":"Pfeifer","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bcp.2026.118440_b1000","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/leu.2012.5","article-title":"Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia","volume":"26","author":"Pfeifer","year":"2012","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.bcp.2026.118440_b1005","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/cncr.28522","volume":"120","author":"Soverini","year":"2014","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.bcp.2026.118440_b1010","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/leu.2016.17","article-title":"Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients","volume":"30","author":"Soverini","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bcp.2026.118440_b1015","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.bcp.2026.118440_b1020","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"issue":"7647","key":"10.1016\/j.bcp.2026.118440_b1025","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bcp.2026.118440_b1030","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.bcp.2026.118440_b1035","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1038\/s41375-025-02709-0","article-title":"Heat stress targets and degrades BCR::ABL1 oncoproteins to overcome drug-resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"39","author":"Yang","year":"2025","journal-title":"Leukemia"},{"issue":"7191","key":"10.1016\/j.bcp.2026.118440_b1040","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","article-title":"BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros","volume":"453","author":"Mullighan","year":"2008","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bcp.2026.118440_b1045","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ccell.2015.07.016","article-title":"Efficacy of retinoids in IKZF1-mutated BCR-ABL1 acute lymphoblastic leukemia","volume":"28","author":"Churchman","year":"2015","journal-title":"Cancer Cell"},{"issue":"23","key":"10.1016\/j.bcp.2026.118440_b1050","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.1158\/1078-0432.CCR-11-1227","article-title":"CDKN2A\/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients","volume":"17","author":"Iacobucci","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.bcp.2026.118440_b1055","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/bloodadvances.2023012162","article-title":"Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations","volume":"8","author":"van Outersterp","year":"2024","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.bcp.2026.118440_b1060","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ng1343","article-title":"Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia","volume":"36","author":"Hu","year":"2004","journal-title":"Nat. Genet."},{"issue":"7347","key":"10.1016\/j.bcp.2026.118440_b1065","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature09883","article-title":"BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition","volume":"473","author":"Duy","year":"2011","journal-title":"Nature"},{"issue":"354","key":"10.1016\/j.bcp.2026.118440_b1070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf5309","article-title":"Targeting BCL-2 and ABL\/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"8","author":"Leonard","year":"2016","journal-title":"Sci Transl Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.118440_b1075","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/clpt.2013.208","article-title":"Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib","volume":"95","author":"Eadie","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.bcp.2026.118440_b1080","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1038\/leu.2015.35","article-title":"Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells","volume":"29","author":"L\u00fc","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bcp.2026.118440_b1085","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2026.118440_b1090","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3324\/haematol.2023.283705","article-title":"Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineage-directed therapies","volume":"109","author":"Bataller","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.bcp.2026.118440_b1095","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcp.2026.118440_b1100","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1055\/s-2006-942273","article-title":"Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL","volume":"218","author":"Gudowius","year":"2006","journal-title":"Klin. Padiatr."},{"issue":"2","key":"10.1016\/j.bcp.2026.118440_b1105","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3390\/cancers12020303","article-title":"CD22 expression in B-cell acute lymphoblastic leukemia: biological significance and implications for inotuzumab therapy in adults","volume":"12","author":"Lanza","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bcp.2026.118440_b1110","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/bloodadvances.2018026211","article-title":"Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia","volume":"3","author":"Wynne","year":"2019","journal-title":"Blood Adv."},{"issue":"14","key":"10.1016\/j.bcp.2026.118440_b1115","article-title":"Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations","volume":"3","author":"Rubinstein","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118440_b1120","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-11-0486","article-title":"Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin","volume":"17","author":"Ricart","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118440_b1125","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","article-title":"Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies","volume":"103","author":"DiJoseph","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bcp.2026.118440_b1130","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.bcp.2026.118440_b1135","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118440_b1140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2024023930","article-title":"Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL","volume":"144","author":"Zhao","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bcp.2026.118440_b1145","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41375-022-01576-3","article-title":"Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial","volume":"36","author":"Pennesi","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bcp.2026.118440_b1150","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3892\/or.2024.8749","article-title":"Combining inotuzumab ozogamicin with PARP inhibitors olaparib and talazoparib exerts synergistic cytotoxicity in acute lymphoblastic leukemia by inhibiting DNA strand break repair","volume":"52","author":"Ida","year":"2024","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2026.118440_b1155","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2141.2009.07701.x","article-title":"CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma","volume":"146","author":"Takeshita","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118440_b1160","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/jcpt.13741","article-title":"The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials","volume":"47","author":"Mocquot","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"issue":"10","key":"10.1016\/j.bcp.2026.118440_b1165","first-page":"757","article-title":"Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia","volume":"18","author":"Le Jeune","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2026.118440_b1170","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.htct.2023.06.006","article-title":"All about blinatumomab: the bispecific T cell engager immunotherapy for B cell acute lymphoblastic leukemia","volume":"46","author":"Mirfakhraie","year":"2024","journal-title":"Hematol Transfus Cell Ther."},{"issue":"9","key":"10.1016\/j.bcp.2026.118440_b1175","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.bcp.2026.118440_b1180","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2026.118440_b1185","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/1574884713666180518102514","article-title":"Pharmacokinetic and pharmacodynamic relationship of blinatumomab in patients with non-hodgkin lymphoma","volume":"13","author":"Hijazi","year":"2018","journal-title":"Curr. Clin. Pharmacol."},{"issue":"15","key":"10.1016\/j.bcp.2026.118440_b1190","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1182\/bloodadvances.2025015894","article-title":"T-cell dysfunction during blinatumomab therapy in pediatric acute lymphoblastic leukemia","volume":"9","author":"Ma","year":"2025","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.bcp.2026.118440_b1195","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/hematology.2019000018","article-title":"Mechanisms of and approaches to overcoming resistance to immunotherapy","volume":"2019","author":"Schultz","year":"2019","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"10","key":"10.1016\/j.bcp.2026.118440_b1200","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2026.118440_b1205","first-page":"38","article-title":"A step forward in the treatment of b-cell precursor acute lymphoblastic leukemia","volume":"9","author":"Drawdy","year":"2019","journal-title":"J. Hematol. Oncol. Pharm."},{"issue":"10","key":"10.1016\/j.bcp.2026.118440_b1210","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003354","article-title":"4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells","volume":"9","author":"Roselli","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.bcp.2026.118440_b1215","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.bcp.2026.118440_b1220","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118440_b1225","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189519","article-title":"The race between 4-1BB- and CD28-based CD19 CAR-T products in the therapy of B-cell malignancies","volume":"1881","author":"Krawczyk","year":"2026","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"14","key":"10.1016\/j.bcp.2026.118440_b1230","article-title":"Analysis of causes for poor persistence of CAR-T cell therapy in vivo","volume":"25","author":"Kong","year":"2023","journal-title":"Front. Immunol."},{"issue":"18","key":"10.1016\/j.bcp.2026.118440_b1235","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.omto.2020.06.016","article-title":"Efficacy and safety of CD28- or 4-1BB-based CD19 CAR-T cells in B cell acute lymphoblastic leukemia","volume":"24","author":"Zhao","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"issue":"3","key":"10.1016\/j.bcp.2026.118440_b1240","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/bloodadvances.2019000525","article-title":"Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed\/refractory DLBCL","volume":"4","author":"Awasthi","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.bcp.2026.118440_b1245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226007793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226007793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:55:39Z","timestamp":1789667739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226007793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":249,"alternative-id":["S0006295226007793"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118440","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute leukemia therapy at a crossroads: from conventional chemotherapy to the era of precision medicine","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118440","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"118440"}}